Ustekinumab in Pediatric Crohn’s disease
In this multi-center study (@ChuSteJustine @HopitalChildren @BCCHF @HopRobertDebre), we found that children living with #crohnsdisease who failed at least 1 antiTNF, had at 12 months,
38.6% clinical remission
47.8% clinical response
with #ustekinumab
#Jantchoulab
